Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing [Yahoo! Finance]
Eterna Therapeutics Inc. (ERNA)
Company Research
Source: Yahoo! Finance
regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock Market. Eterna received formal confirmation on November 12th, 2024 from Nasdaq's Office of General Counsel, verifying that Eterna has met the market value of listed securities standard of at least $35 million, outlined in Listing Rule 5550(b)(2), and that Eterna is in compliance with all applicable continued listing standards. “With this achievement and the recent updates we've announced, we have transformed our company into a debt-free, low burn rate, fully functional preclinical stage cell therapy company with clear, focused developmental activities and near-term inflection points,” said Sanjeev Luther, President and CEO of Eterna Therapeutics. “With this compliance milestone behind us, we can continue to be laser focused on advancing ERNA-101 for our lead programs in triple-negative breast cancer and platinum-resistant, TP53-mutant ovarian cancer. Our goal remains t
Show less
Read more
Impact Snapshot
Event Time:
ERNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERNA alerts
High impacting Eterna Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ERNA
News
- Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models [Yahoo! Finance]Yahoo! Finance
- Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer ModelsGlobeNewswire
- Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program [Yahoo! Finance]Yahoo! Finance
- Eterna Therapeutics Announces Up to $1 Million Stock Repurchase ProgramGlobeNewswire
- Eterna Therapeutics Regains Compliance with NASDAQ for Continued ListingGlobeNewswire
ERNA
Sec Filings
- 11/18/24 - Form 424B3
- 11/18/24 - Form 424B3
- 11/18/24 - Form 424B3
- ERNA's page on the SEC website